

Julio S G Montaner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5363961/publications.pdf>

Version: 2024-02-01

108
papers

3,423
citations

136950

32
h-index

168389

53
g-index

116
all docs

116
docs citations

116
times ranked

4521
citing authors

#	ARTICLE	IF	CITATIONS
1	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. <i>Journal of Infectious Diseases</i> , 2023, 227, 838-849.	4.0	31
2	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140.	4.0	65
3	Neighbourhood-level material deprivation and response to combination antiretroviral therapy in the Canadian Observational Cohort (CANOC): a longitudinal cohort study. <i>CMAJ Open</i> , 2022, 10, E183-E189.	2.4	0
4	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	6.0	64
5	The opioid crisis is driving mortality among under-served people living with HIV in British Columbia, Canada. <i>BMC Public Health</i> , 2021, 21, 680.	2.9	5
6	Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada?. <i>Epidemics</i> , 2021, 35, 100461.	3.0	3
7	SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 907-919.	2.8	17
8	Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 338-348.	2.5	5
9	Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab492.	0.9	1
10	Crystal Methamphetamine Use and Initiation among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV in a Treatment as Prevention Environment. <i>Substance Use and Misuse</i> , 2020, 55, 2428-2437.	1.4	11
11	The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada. <i>Current HIV/AIDS Reports</i> , 2020, 17, 77-87.	3.1	16
12	Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. <i>Journal of Infectious Diseases</i> , 2020, 222, 899-902.	4.0	75
13	Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. <i>PLoS Medicine</i> , 2020, 17, e1003172.	8.4	32
14	Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa488.	0.9	21
15	Incidence of select chronic comorbidities among a population-based cohort of HIV-positive individuals receiving highly active antiretroviral therapy. <i>Current Medical Research and Opinion</i> , 2019, 35, 1955-1963.	1.9	12
16	Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources. <i>EBioMedicine</i> , 2019, 48, 405-413.	6.1	8
17	Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. <i>Pharmacoeconomics</i> , 2019, 37, 1219-1239.	3.3	7
18	Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 207-215.	2.1	1

#	ARTICLE	IF	CITATIONS
19	Factors associated with delayed and late ART initiation among people living with HIV in BC: results from the engage study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 885-892.	1.2	9
20	Declining Mortality Rates in HIV-Infected People Who Inject Drugs During a Seek-and-Treat Initiative in Vancouver, Canada, 1996â€“2014: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 64-68.	4.0	7
21	Trends in discharges from the HIV/AIDS ward at a tertiary Canadian Hospital from 2005 to 2014. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1099-1106.	1.2	6
22	Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. <i>BMJ Open</i> , 2018, 8, e019115.	1.9	17
23	Trends in Awareness and Use of HIV PrEP Among Gay, Bisexual, and Other Men who have Sex with Men in Vancouver, Canada 2012â€“2016. <i>AIDS and Behavior</i> , 2018, 22, 3550-3565.	2.7	37
24	Assessing the relationship between physician availability and viral load suppression in British Columbia. <i>Canadian Geographer / Geographie Canadien</i> , 2018, 62, 120-129.	1.5	0
25	Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. <i>AIDS and Behavior</i> , 2018, 22, 1530-1540.	2.7	6
26	Factors associated with low neighborhood cohesion among women living with HIV impacted by social-structural inequities in British Columbia. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 318-324.	1.2	3
27	Expert consensus statement on the science of <sc>HIV</sc> in the context of criminal law. <i>Journal of the International AIDS Society</i> , 2018, 21, e25161.	3.0	59
28	Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada. <i>Sexually Transmitted Infections</i> , 2017, 93, 284-289.	1.9	9
29	Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. <i>BMC Infectious Diseases</i> , 2017, 17, 174.	2.9	87
30	Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. <i>Lancet HIV,the</i> , 2017, 4, e270-e276.	4.7	51
31	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996â€“2013: a modelling study. <i>Lancet HIV,the</i> , 2017, 4, e303-e310.	4.7	31
32	Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996â€“2015. <i>Clinical Infectious Diseases</i> , 2017, 65, 1496-1503.	5.8	10
33	Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada. <i>Antiviral Therapy</i> , 2017, 22, 403-411.	1.0	7
34	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naÃ“ve patients. <i>BMC Infectious Diseases</i> , 2017, 17, 266.	2.9	7
35	Harder-to-reach people living with HIV experiencing high prevalence of all-type mental health disorder diagnosis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 696-704.	1.2	9
36	Progress towards the United Nations 90â€“90â€“90 and 95â€“95â€“95 targets: the experience in British Columbia, Canada. <i>Journal of the International AIDS Society</i> , 2017, 20, e25011.	3.0	28

#	ARTICLE	IF	CITATIONS
37	A latent class analysis of sexual and romantic relationships among HIV-positive and HIV-negative gay and bisexual men in Vancouver. <i>Canadian Journal of Human Sexuality</i> , 2017, 26, 78-96.	1.6	2
38	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. <i>Current Infectious Disease Reports</i> , 2016, 18, 22.	3.0	14
39	The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 698-702.	9.1	41
40	Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study. <i>Lancet HIV</i> ,the, 2016, 3, e231-e238.	4.7	168
41	Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 455.	2.9	17
42	Heightened epidemic in men who have sex with men in Brazil. <i>Lancet HIV</i> ,the, 2016, 3, e454-e455.	4.7	0
43	Achieving the 90â€“90â€“90 target: incentives for HIV testing. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1215-1216.	9.1	11
44	Suicide mortality among people accessing highly active antiretroviral therapy for HIV/AIDS in British Columbia: a retrospective analysis. <i>CMAJ Open</i> , 2015, 3, E140-E148.	2.4	30
45	The impact of scalingâ€“up combination antiretroviral therapy on patterns of mortality among HIVâ€“positive persons in British Columbia, Canada. <i>Journal of the International AIDS Society</i> , 2015, 18, 20261.	3.0	29
46	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. <i>Journal of the International AIDS Society</i> , 2015, 18, 20024.	3.0	22
47	The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. <i>PLoS ONE</i> , 2015, 10, e0123482.	2.5	10
48	The need for standardisation of the HIV continuum of care. <i>Lancet HIV</i> ,the, 2015, 2, e225-e226.	4.7	16
49	Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. <i>Lancet HIV</i> ,the, 2015, 2, e393-e400.	4.7	36
50	The Impact of Clinical, Demographic and Risk Factors on Rates of HIV Transmission: A Population-based Phylogenetic Analysis in British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2015, 211, 926-935.	4.0	89
51	The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015, 61, 1157-1165.	5.8	48
52	Denial of prescription analgesia among people who inject drugs in a <sc>C</sc>anadian setting. <i>Drug and Alcohol Review</i> , 2015, 34, 221-228.	2.1	47
53	Global Origin and Transmission of Hepatitis C Virus Nonstructural Protein 3 Q80K Polymorphism. <i>Journal of Infectious Diseases</i> , 2015, 211, 1288-1295.	4.0	44
54	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort. <i>International Journal of Epidemiology</i> , 2015, 44, 58-67.	1.9	31

#	ARTICLE	IF	CITATIONS
55	Gender Inequities in Quality of Care among HIV-Positive Individuals Initiating Antiretroviral Treatment in British Columbia, Canada (2000â€“2010). PLoS ONE, 2014, 9, e92334.	2.5	40
56	Association between Childhood Physical Abuse, Unprotected Receptive Anal Intercourse and HIV Infection among Young Men Who Have Sex with Men in Vancouver, Canada. PLoS ONE, 2014, 9, e100501.	2.5	18
57	High Levels of Heterogeneity in the HIV Cascade of Care across Different Population Subgroups in British Columbia, Canada. PLoS ONE, 2014, 9, e115277.	2.5	62
58	Comparing the efficacy of efavirenz and boosted lopinavir using viremia copyâ€¦years. Journal of the International AIDS Society, 2014, 17, 18617.	3.0	7
59	Predictors of liverâ€¦related death among people who inject drugs in Vancouver, Canada: a 15â€¦year prospective cohort study. Journal of the International AIDS Society, 2014, 17, 19296.	3.0	8
60	Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 459-465.	1.2	19
61	High rates of lifetime and recent violence observed among harder-to-reach women living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 587-594.	1.2	17
62	The effect of history of injection drug use and alcoholism on HIV disease progression. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 123-129.	1.2	16
63	The impact of unstable housing on emergency department use in a cohort of HIV-positive people in a Canadian setting. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 53-64.	1.2	8
64	Cohort Profile: Seek and Treat for the Optimal Prevention of HIV/AIDS in British Columbia (STOP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	1.9	56
65	Health and social harms associated with crystal methamphetamine use among street-involved youth in a Canadian setting. American Journal on Addictions, 2014, 23, 393-398.	1.4	20
66	Does This Adult Patient Have Early HIV Infection?. JAMA - Journal of the American Medical Association, 2014, 312, 278.	7.4	26
67	Antiretroviral treatment initiation â€œ Authors' reply. Lancet Infectious Diseases, The, 2014, 14, 1176-1177.	9.1	0
68	HIV treatment strategies that can weather future challenges. Lancet Infectious Diseases, The, 2014, 14, 534-535.	9.1	1
69	Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The â€œHIV Treatment as Preventionâ€•Experience in a Canadian Setting. PLoS ONE, 2014, 9, e87872.	2.5	272
70	Identifying self-perceived HIV-related stigma in a population accessing antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 95-102.	1.2	21
71	Socialâ€•structural factors associated with supportive service use among a cohort of HIV-positive individuals on antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 937-947.	1.2	3
72	CD4 T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis. Antiviral Therapy, 2013, 19, 31-39.	1.0	11

#	ARTICLE	IF	CITATIONS
73	Gender Differences in Clinical Outcomes among HIV-Positive Individuals on Antiretroviral Therapy in Canada: A Multisite Cohort Study. PLoS ONE, 2013, 8, e83649.	2.5	39
74	Availability of nutritional support services in HIV care and treatment sites in sub-Saharan African countries. Public Health Nutrition, 2012, 15, 938-947.	2.2	31
75	“The way I see it” the effect of stigma and depression on self-perceived body image among HIV-positive individuals on treatment in British Columbia, Canada. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 1456-1466.	1.2	17
76	Individual, Social, and Environmental Factors Associated with Initiating Methamphetamine Injection: Implications for Drug Use and HIV Prevention Strategies. Prevention Science, 2011, 12, 173-180.	2.6	39
77	Home is where the HAART is: an examination of factors affecting neighbourhood perceptions among people with HIV/AIDS on antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 245-251.	1.2	7
78	Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 980-987.	1.2	39
79	Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection. Clinical Infectious Diseases, 2010, 50, 98-105.	5.8	114
80	HIV antiviral drug resistance: patient comprehension. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 816-826.	1.2	15
81	Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study. Antiviral Therapy, 2009, 14, 931-938.	1.0	20
82	Incorporation of ANTI-HHV-8 Agents as Targeted Therapy for the Treatment of HIV-Associated Primary Effusion Lymphoma.. Blood, 2009, 114, 4768-4768.	1.4	0
83	Burden of HIV Infection Among Aboriginal Injection Drug Users in Vancouver, British Columbia. American Journal of Public Health, 2008, 98, 515-519.	2.7	56
84	Factors Associated with Public Injecting Among Users of Vancouver's Supervised Injection Facility. American Journal of Drug and Alcohol Abuse, 2007, 33, 319-325.	2.1	45
85	Circumstances of First Injection Among Illicit Drug Users Accessing a Medically Supervised Safer Injection Facility. American Journal of Public Health, 2007, 97, 1228-1230.	2.7	33
86	Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver. Antiviral Therapy, 2007, 12, 1139-1144.	1.0	3
87	Short Communication: HIV VprR77Q Mutation Does Not Influence Clinical Response of Individuals Initiating Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2006, 22, 615-618.	1.1	13
88	Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naïve, HIV-infected patients. MedGenMed: Medscape General Medicine, 2006, 8, 36.	0.2	6
89	Factors associated with sex-trade involvement among female injection drug users in a Canadian setting. Addiction Research and Theory, 2005, 13, 193-199.	1.9	16
90	Association of the CCR5 Δ 32 Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen. Antiviral Therapy, 2005, 10, 849-853.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes. <i>Antiviral Therapy</i> , 2004, 9, 713-719.	1.0	104
92	Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users. <i>Antiviral Therapy</i> , 2004, 9, 229-235.	1.0	56
93	Mitochondrial Toxicity in the Era of HAART: Evaluating Venous Lactate and Peripheral Blood Mitochondrial DNA in HIV-Infected Patients Taking Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, S85-S90.	2.1	61
94	Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 $\times 10^9$ cells/L. <i>Annals of Internal Medicine</i> , 2003, 139, 810.	3.9	323
95	Prevalence and clinical implications of insertions in the HIV-1 p6 ^{Gag} N-terminal region in drug-naïve individuals initiating antiretroviral therapy. <i>Antiviral Therapy</i> , 2003, 8, 91-96.	1.0	16
96	Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings. <i>Antiviral Therapy</i> , 2003, 8, 379-384.	1.0	16
97	Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme. <i>Antiviral Therapy</i> , 2003, 8, 569-576.	1.0	19
98	Management of HIV-infected patients with multidrug-resistant virus. <i>Current Infectious Disease Reports</i> , 2002, 4, 259-265.	3.0	2
99	Clinical uses of non-nucleoside reverse transcriptase inhibitors. <i>Reviews in Medical Virology</i> , 2000, 10, 217-229.	8.3	37
100	Clinical uses of non-nucleoside reverse transcriptase inhibitors. <i>Reviews in Medical Virology</i> , 2000, 10, 217-229.	8.3	2
101	Antiretroviral Effect of Two Different Dose Regimens of Ritonavir and Saquinavir on HIV-Infected Adults in a Population-Based Setting. <i>Antiviral Therapy</i> , 1999, 4, 151-156.	1.0	0
102	Modelling the Potential Economic Impact of Viral Load-Driven Triple Drug Combination Antiretroviral Therapy. <i>Pharmacoeconomics</i> , 1998, 13, 697-705.	3.3	25
103	Antiviral effect of double and triple drug combinations amongst HIV-infected adults. <i>Aids</i> , 1998, 12, 279-284.	2.2	79
104	Diminished HIV-1 Sensitivity to Stavudine in Patients on Prolonged Therapy Occurs Only at Low Levels and Cannot be Attributed to Any Single Amino Acid Substitution in Reverse Transcriptase. <i>Antiviral Therapy</i> , 1998, 3, 177-182.	1.0	7
105	A Pilot Study of Hydroxyurea among Patients with Advanced Human Immunodeficiency Virus (HIV) Disease Receiving Chronic Didanosine Therapy: Canadian HIV Trials Network Protocol 080. <i>Journal of Infectious Diseases</i> , 1997, 175, 801-806.	4.0	84
106	Stavudine plus Lamivudine in Advanced Human Immunodeficiency Virus Disease: A Short-Term Pilot Study. <i>Journal of Infectious Diseases</i> , 1997, 176, 1156-1160.	4.0	13
107	Asthma Mortality in Canada, 1946 to 1990. <i>Canadian Respiratory Journal</i> , 1995, 2, 61-66.	1.6	10
108	Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT-Resistant Variants of HIV-1. <i>Annals of the New York Academy of Sciences</i> , 1990, 616, 346-355.	3.8	20